SARS-CoV-2 Omicron infection is associated with high nasopharyngeal viral load

[1]  S. Katikireddi,et al.  Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil , 2022, Nature Medicine.

[2]  G. Lippi,et al.  Is SARS-CoV-2 Omicron (B.1.1.529) variant causing different symptoms? , 2022, Journal of Infection.

[3]  Zhongyi Wang,et al.  High amounts of SARS-CoV-2 in aerosols exhaled by patients with Omicron variant infection , 2022, Journal of Infection.

[4]  G. Hindricks,et al.  A Comparative Analysis of In-Hospital Mortality per Disease Groups in Germany Before and During the COVID-19 Pandemic From 2016 to 2020 , 2022, JAMA network open.

[5]  L. Zou,et al.  Early predictive value of platelet function for clinical outcome in sepsis. , 2022, The Journal of infection.

[6]  S. Raymond,et al.  Influence of immune escape and nasopharyngeal virus load on the spread of SARS-CoV-2 Omicron variant , 2022, Journal of Infection.

[7]  J. Izopet,et al.  Antibody titers and breakthrough infections with Omicron SARS-CoV-2 , 2022, Journal of Infection.

[8]  I. Boutron,et al.  Interleukin-1 blocking agents for treating COVID-19. , 2022, The Cochrane database of systematic reviews.

[9]  Shunming Zhang,et al.  The occurrence and risk factors associated with post‐traumatic stress disorder among discharged COVID‐19 patients in Tianjin, China , 2022, Brain and behavior.

[10]  S. Schrag,et al.  Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants. , 2022, JAMA.

[11]  K. Swanson,et al.  Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine–elicited human sera , 2022, Science.

[12]  C. Riou,et al.  Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose , 2022, The Lancet.

[13]  J. Li,et al.  Regular and booster vaccination with inactivated vaccines enhance the neutralizing activity against Omicron variant both in the breakthrough infections and vaccinees , 2022, Journal of Infection.

[14]  S. Madhi,et al.  SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses , 2022, Cell.

[15]  Jordan J. Clark,et al.  Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron , 2021, Nature.

[16]  P. Maes,et al.  Considerable escape of SARS-CoV-2 Omicron to antibody neutralization , 2021, Nature.

[17]  A. Mastroianni,et al.  Early use of canakinumab to prevent mechanical ventilation in select COVID-19 patients: A retrospective, observational analysis , 2021, International journal of immunopathology and pharmacology.

[18]  S. Gharbia,et al.  Effectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of concern , 2021, medRxiv.

[19]  J. Kimpel,et al.  SARS-CoV-2 B.1.1.529 variant (Omicron) evades neutralization by sera from vaccinated and convalescent individuals , 2021, medRxiv.

[20]  A. Rabaan,et al.  Infection risk with the use of interleukin inhibitors in hospitalized patients with COVID-19: A narrative review. , 2021, Le infezioni in medicina.

[21]  A. Sigal,et al.  SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection , 2021, medRxiv.

[22]  J. Koeleman,et al.  SARS-CoV-2 antibody and T cell responses one year after COVID-19 and the booster effect of vaccination: A prospective cohort study , 2021, Journal of Infection.

[23]  S. Karim,et al.  Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic , 2021, The Lancet.

[24]  Scott M Elliott,et al.  Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial , 2021, The Lancet.

[25]  M. Peiris,et al.  A RCT of a third dose CoronaVac or BNT162b2 vaccine in adults with two doses of CoronaVac , 2021, medRxiv.

[26]  C. Charpentier,et al.  Alpha (B.1.1.7) and Delta (B.1.617.2 – AY.40) SARS-CoV-2 variants present strong neutralization decay at M4 post-vaccination and a faster replication rates than D614G (B.1) lineage , 2021, Journal of Infection.

[27]  S. Mallapaty.  China’s COVID vaccines have been crucial — now immunity is waning , 2021, Nature.

[28]  E. Albert,et al.  Evolution of SARS-CoV-2 immune responses in nursing home residents following full dose of the Comirnaty® COVID-19 vaccine , 2021, Journal of Infection.

[29]  M. Afzal,et al.  War-torn Afghanistan - potential risk to the polio eradication efforts: A call for global concern! , 2021, The Journal of infection.

[30]  E. Albert,et al.  Immunological response against SARS-CoV-2 following full-dose administration of Comirnaty® COVID-19 vaccine in nursing home residents , 2021, Clinical Microbiology and Infection.

[31]  C. Struchiner,et al.  Effectiveness of Mass Vaccination in Brazil against Severe COVID-19 Cases , 2021, medRxiv.

[32]  J. V. Van Praet,et al.  Dynamics of the cellular and humoral immune response after BNT162b2 mRNA Covid-19 vaccination in Covid-19 naive nursing home residents. , 2021, The Journal of infectious diseases.

[33]  C. Charpentier,et al.  Decreasing humoral response among healthcare workers up to 4 months after two doses of BNT162b2 vaccine , 2021, Journal of Infection.

[34]  M. Gao,et al.  Bamlanivimab improves hospitalization and mortality rates in patients with COVID-19: A systematic review and meta-analysis , 2021, Journal of Infection.

[35]  L. Tserel,et al.  Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study , 2021, The Lancet Regional Health - Europe.

[36]  M. Vekemans,et al.  Immunogenicity of mRNA-1273 COVID vaccine after 6 months surveillance in health care workers; a third dose is necessary , 2021, The Journal of Infection.

[37]  G. Wegener,et al.  Psychiatric and neuropsychiatric sequelae of COVID-19 – A systematic review , 2021, Brain, Behavior, and Immunity.

[38]  A. Lincoff,et al.  Double-blind randomized proof-of-concept trial of canakinumab in patients with COVID-19 associated cardiac injury and heightened inflammation , 2021, European heart journal open.

[39]  M. Afzal,et al.  Emerging polio hotspots in Pakistan: Challenges and the way forward , 2021, Journal of Infection.

[40]  A. Abbate,et al.  Effect of Canakinumab vs Placebo on Survival Without Invasive Mechanical Ventilation in Patients Hospitalized With Severe COVID-19: A Randomized Clinical Trial. , 2021, JAMA.

[41]  Howard H. Chang,et al.  Estimating under-recognized COVID-19 deaths, United States, march 2020-may 2021 using an excess mortality modelling approach , 2021, The Lancet Regional Health - Americas.

[42]  S. Virani,et al.  Disease-Specific Excess Mortality During the COVID-19 Pandemic: An Analysis of Weekly US Death Data for 2020. , 2021, American journal of public health.

[43]  M. Picot,et al.  Antibody response after one and two jabs of the BNT162b2 vaccine in nursing home residents: The CONsort‐19 study , 2021, Allergy.

[44]  S. Hunziker,et al.  Prevalence and factors associated with psychological burden in COVID-19 patients and their relatives: A prospective observational cohort study , 2021, PloS one.

[45]  S. Preston,et al.  COVID-19 and excess mortality in the United States: A county-level analysis , 2021, PLoS medicine.

[46]  J. Izopet,et al.  Influence of SARS-CoV-2 Variant B.1.1.7, Vaccination, and Public Health Measures on the Spread of SARS-CoV-2 , 2021, Viruses.

[47]  D. Gregori,et al.  Excess of all-cause mortality is only partially explained by COVID-19 in Veneto (Italy) during spring outbreak , 2021, BMC Public Health.

[48]  G. d’Ettorre,et al.  Post-traumatic Stress Disorder Among COVID-19 Survivors at 3-Month Follow-up After Hospital Discharge , 2021, Journal of General Internal Medicine.

[49]  V. Lauschke,et al.  Immunogenicity of the BNT162b2 vaccine in frail or disabled nursing home residents: COVID‐A study , 2021, Journal of the American Geriatrics Society.

[50]  E. Cendejas-Bueno,et al.  Detection of Neisseria meningitidis in a patient receiving ravulizumab by the FilmArray® Meningitis/Encephalitis panel- A case report. , 2021, The Journal of infection.

[51]  K. Ella,et al.  Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial , 2021, The Lancet Infectious Diseases.

[52]  Head-to-head comparison of two rapid high-throughput automated electrochemiluminescence immunoassays targeting total antibodies to the SARS-CoV-2 nucleoprotein and spike protein receptor binding domain , 2021, Journal of Clinical Virology.

[53]  W. Ko,et al.  The impact of the coronavirus disease 2019 epidemic on notifiable infectious diseases in Taiwan: A database analysis , 2021, Travel Medicine and Infectious Disease.

[54]  H. Mouquet,et al.  Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies , 2021, Nature Medicine.

[55]  M. Reeves,et al.  Validation of a commercially available indirect assay for SARS-CoV-2 neutralising antibodies using a pseudotyped virus assay , 2021, Journal of Infection.

[56]  Mi-Kyung Lee,et al.  Duration of Culturable SARS-CoV-2 in Hospitalized Patients with Covid-19 , 2021, The New England journal of medicine.

[57]  F. Cipollone,et al.  Efficacy of canakinumab in mild or severe COVID‐19 pneumonia , 2021, Immunity, inflammation and disease.

[58]  M. M. van der Eerden,et al.  Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19) , 2021, Nature communications.

[59]  S. Balkan,et al.  Concomitant Treatment of Chronic Hepatitis C With Direct-Acting Antivirals and Multidrug-Resistant Tuberculosis Is Effective and Safe , 2021, Open forum infectious diseases.

[60]  Ji-yang Liu,et al.  Prevalence and predictors of post-traumatic stress disorder in patients with cured coronavirus disease 2019 (COVID-19) one month post-discharge , 2021, European journal of psychotraumatology.

[61]  J. Dushoff,et al.  Increased risk of SARS-CoV-2 reinfection associated with emergence of the Omicron variant in South Africa , 2021 .

[62]  D. Generali,et al.  Canakinumab as treatment for COVID-19-related pneumonia: A prospective case-control study , 2020, International Journal of Infectious Diseases.

[63]  G. Hindricks,et al.  Regional and temporal disparities of excess all-cause mortality for Germany in 2020: is there more than just COVID-19? , 2020, The Journal of infection.

[64]  H. Park,et al.  Psychological Consequences of Survivors of COVID-19 Pneumonia 1 Month after Discharge , 2020, Journal of Korean medical science.

[65]  A. Zangrillo,et al.  Residual clinical damage after COVID-19: A retrospective and prospective observational cohort study , 2020, PloS one.

[66]  D. Hervás,et al.  Short‐term neuropsychiatric outcomes and quality of life in COVID‐19 survivors , 2020, medRxiv.

[67]  P. Cattani,et al.  Evaluation of three commercial assays for SARS-CoV-2 molecular detection in upper respiratory tract samples , 2020, European Journal of Clinical Microbiology & Infectious Diseases.

[68]  Ossama K. Abou Hassan,et al.  Canakinumab to reduce deterioration of cardiac and respiratory function in SARS‐CoV‐2 associated myocardial injury with heightened inflammation (canakinumab in Covid‐19 cardiac injury: The three C study) , 2020, Clinical cardiology.

[69]  I. Valentini,et al.  Sixty-Day Mortality Among 520 Italian Hospitalized COVID-19 Patients According to the Adopted Ventilatory Strategy in the Context of an Integrated Multidisciplinary Clinical Organization: A Population-Based Cohort Study , 2020, medRxiv.

[70]  Nina Dwi Putri,et al.  Meningococcal disease surveillance in the Asia-Pacific region (2020): the Global Meningococcal Initiative. , 2020, The Journal of infection.

[71]  Eric Song,et al.  Longitudinal analyses reveal immunological misfiring in severe COVID-19 , 2020, Nature.

[72]  Céline Caserio-Schönemann,et al.  Excess all-cause mortality during the COVID-19 pandemic in Europe – preliminary pooled estimates from the EuroMOMO network, March to April 2020 , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[73]  Patricia Harrington,et al.  SARS-CoV-2 detection, viral load and infectivity over the course of an infection , 2020, Journal of Infection.

[74]  M. Rugge,et al.  Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (N = 4532) , 2020, Annals of Oncology.

[75]  Dowan Kim,et al.  Sepsis-induced cardiac dysfunction: a review of pathophysiology , 2020, Acute and critical care.

[76]  Benjamin J. Polacco,et al.  A SARS-CoV-2 Protein Interaction Map Reveals Targets for Drug-Repurposing , 2020, Nature.

[77]  Yi Wang,et al.  Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial , 2020, The Lancet.

[78]  D. Boulware,et al.  Methods for rapid diagnosis of meningitis etiology in adults , 2020, Biomarkers in medicine.

[79]  M. Franke,et al.  High prevalence of hepatitis C infection among multidrug-resistant tuberculosis patients. , 2020, Journal of hepatology.

[80]  A. Sugunan,et al.  Neutralizing antibody responses to SARS-CoV-2 in COVID-19 patients , 2020, The Indian journal of medical research.

[81]  M. Senna,et al.  Topical Antiandrogen Therapies for Androgenetic Alopecia and Acne Vulgaris , 2019, American Journal of Clinical Dermatology.

[82]  M. Nelson,et al.  Higher sustained virological response rates at 12 weeks in HIV-HCV co-infection; a tertiary centre experience. , 2019, The Journal of infection.

[83]  D. Goletti,et al.  Hepatitis C virus infection: a challenge in the complex management of two cases of multidrug-resistant tuberculosis , 2019, BMC Infectious Diseases.

[84]  R. Kempker,et al.  A Pharmacology Perspective on Simultaneous Tuberculosis and Hepatitis C Treatment , 2019, Antimicrobial Agents and Chemotherapy.

[85]  S. Tong,et al.  When Ventricular Cerebrospinal Fluid Assessment Misleads: Basal Meningitis and the Importance of Lumbar Puncture Sampling , 2019, Open forum infectious diseases.

[86]  P. Hsueh,et al.  Usefulness of the FilmArray meningitis/encephalitis (M/E) panel for the diagnosis of infectious meningitis and encephalitis in Taiwan. , 2019, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.

[87]  Y. Iwadate,et al.  Correlation between vancomycin penetration into cerebrospinal fluid and protein concentration in cerebrospinal fluid/serum albumin ratio. , 2019, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[88]  M. Behzadifar,et al.  Prevalence of Hepatitis C Virus in Tuberculosis Patients: A Systematic Review and Meta-Analysis , 2019, Ethiopian journal of health sciences.

[89]  F. van Leth,et al.  The Tuberculosis Network European Trials group (TBnet) ERS Clinical Research Collaboration: addressing drug-resistant tuberculosis through European cooperation , 2019, European Respiratory Journal.

[90]  M. Taheri,et al.  Administration of Vancomycin at High Doses in Patients with Post Neurosurgical Meningitis: A Comprehensive Comparison between Continuous Infusion and Intermittent Infusion , 2018, Iranian journal of pharmaceutical research : IJPR.

[91]  M. D. Giudice,et al.  Rethinking IL-6 and CRP: Why they are more than inflammatory biomarkers, and why it matters , 2018, Brain, Behavior, and Immunity.

[92]  D. Angiolillo,et al.  Canakinumab for secondary prevention of atherosclerotic disease , 2018, Expert opinion on biological therapy.

[93]  G. Indolfi.  Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection , 2018 .

[94]  D. Weber,et al.  Vancomycin Minimum Inhibitory Concentration Is Not a Substitute for Clinical Judgment: Response to Healthcare-Associated Ventriculitis and Meningitis. , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[95]  Jordi Rello,et al.  Cardiac arrest among patients with infections: causes, clinical practice and research implications. , 2017, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[96]  Shuo-Ming Ou,et al.  Association of weekend effect with early mortality in severe sepsis patients over time. , 2017, The Journal of infection.

[97]  J. Briegel,et al.  Cerebrospinal fluid penetration of meropenem in neurocritical care patients with proven or suspected ventriculitis: a prospective observational study , 2016, Critical Care.

[98]  S. Gupta,et al.  Androgen receptor‐related diseases: what do we know? , 2016, Andrology.

[99]  R. Shebl,et al.  Outcome of community-acquired pneumonia with cardiac complications , 2015 .

[100]  D. Talwar,et al.  Systemic Inflammation Predicts All-Cause Mortality: A Glasgow Inflammation Outcome Study , 2015, PloS one.

[101]  S. Shokouhi,et al.  Determination of vancomycin trough level in serum and cerebrospinal fluid of patients with acute community-acquired meningitis: a prospective study. , 2014, The Journal of infection.

[102]  A. Trampuz,et al.  Characteristics of infections associated with external ventricular drains of cerebrospinal fluid. , 2013, The Journal of infection.

[103]  V. Mabasa,et al.  Systematic Review of Efficacy, Pharmacokinetics, and Administration of Intraventricular Vancomycin in Adults , 2012, Neurocritical Care.

[104]  N. Patel,et al.  Acute Cholecystits Leading to Ischemic ECG Changes in a Patient with No Underlying Cardiac Disease , 2011, JSLS : Journal of the Society of Laparoendoscopic Surgeons.

[105]  F. Sörgel,et al.  Penetration of Drugs through the Blood-Cerebrospinal Fluid/Blood-Brain Barrier for Treatment of Central Nervous System Infections , 2010, Clinical Microbiology Reviews.

[106]  M. McDermott,et al.  Canakinumab, a fully-human mAb against IL-1beta for the potential treatment of inflammatory disorders. , 2009, Current opinion in molecular therapeutics.

[107]  C. Codina,et al.  Are higher vancomycin doses needed in venticle-external shunted patients? , 2006, Pharmacy World and Science.

[108]  C. Dolea,et al.  World Health Organization , 1949, International Organization.